North America Vaccines Market Developments and Forecast by 2027

The North America human vaccines market is expected to reach US$ 24,510.0 Mn in 2027 from US$ 14,566.0 Mn in 2018. The market is estimated to grow with a CAGR of 6.0% from 2019-2027.

The growth of the market is driven by the factors such as compulsion or mandate vaccination and dropping vaccination rates. However, the vaccines market is likely to get impacted due to the low awareness about the benefits of vaccines during the forecast period.

The epidemic of measles in Disneyland in California, US has enforced the dropping of the rates for the vaccination. The instance took place in 2014, the epidemic of the measles has sickened approximately 111 people in California and has also spread to six other states as well as Canada and Mexico. The vaccination has been used safely and effectively for the decades and the rising numbers of the measles has led to more vaccinations. The children are more susceptible to falling prey to the diseases, therefore majority of the parents in US vaccinate their children on schedule.

Additionally, the vaccinations rates are reimbursed by the Medicaid and the reimbursement for Medicaid vaccine administration varies by state however it is as low as US$2 in some states. Also the use of the combination vaccines has been permitted by the Advisory Committee on Immunization Practices (ACIP) at the Centers for Disease Control (CDC). This is a safe and efficacious measure to decrease the number of injections needed to complete the childhood immunization schedule. Hence, the dropping rates of the vaccination rates are likely to raise the market significantly in the forecast period.

US is expected to lead the market in the North American region due to the rapid growth of the biopharmaceutical industry. The industry is experiencing the rapid growth due to technological advancements and increasing flexibility and low operational cost are also adding to the growth of the market. In addition, in the country the government has mandate the immunization and vaccination for preventable diseases. The growth of the market is also defined by the rising prevalence of the infectious and parasitic diseases as the diseases are alarming the need of the vaccination in the country. Therefore, considering the above mentioned factors the growth of the market in the country is likely to contribute largest share in the North American region during the forecast period.

Rest of North America Vaccines Market Revenue and Forecasts to 2027 (US$ Mn)

NORTH AMERICA VACCINES- MARKET SEGMENTATION

By Technology

• Recombinant vaccines
• Conjugate Vaccines
• Live Attenuated Vaccines
• Inactivated Vaccines
• Toxoid Vaccines

NORTH AMERICA VACCINES - MARKET SEGMENTATION

By Disease Indication

• DTP (diphtheria, tetanus, and pertussis)
• Influenza
• Hepatitis
• Other Diseases

NORTH AMERICA VACCINES - MARKET SEGMENTATION

By Rout of Administration

• Oral
• Injectable
• Other

NORTH AMERICA VACCINES - MARKET SEGMENTATION

By Patient Type

• Adults
• Pediatric

By Country

• U.S
• Canada
• Mexico

Companies Mentioned

• PFIZER INC
• GlaxoSmithKline plc.
• Merck & Co., Inc.
• Sanofi
• Johnson & Johnson Services, Inc
• Panacea Biotec Limited
• Astellas Pharma Inc.
• NOVAVAX, INC.
• VBI Vaccines Inc
• Bavarian Nordic.

North America Vaccines Report Scope